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Abstract
Purpose: Stereotactic body radiation therapy (SBRT) is an effective treatment for oligometastatic
or unresectable primary malignancies, although target proximity to organs at risk (OARs) within
the ultracentral thorax (UCT) limits safe delivery of an ablative dose. Stereotactic magnetic
resonance (MR)eguided online adaptive radiation therapy (SMART) may improve the therapeutic
ratio using reoptimization to account for daily variation in target and OAR anatomy. This study
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assessed the feasibility of UCT SMART and characterized dosimetric and clinical outcomes in
patients treated for UCT lesions on a prospective phase 1 trial.
Methods and Materials: Five patients with oligometastatic (nZ 4) or unresectable primary (nZ
1) UCT malignancies underwent SMART. Initial plans prescribed 50 Gy in 5 fractions with goal
95% planning target volume (PTV) coverage by 95% of prescription, subject to strict OAR con-
straints. Daily real-time online adaptive plans were created as needed to preserve hard OAR
constraints, escalate PTV dose, or both, based on daily setup MR image set anatomy. Treatment
times, patient outcomes, and dosimetric comparisons were prospectively recorded.
Results: All initial and daily adaptive plans met strict OAR constraints based on simulation and
daily setup MR imaging anatomy, respectively. Four of the 5 patients received 1 adapted fraction.
Ten of the 25 total delivered fractions were adapted. A total of 30% of plan adaptations were
performed to improve PTV coverage; 70% were for reversal of 1 OAR violation. Local control
by Response Evaluation Criteria in Solid Tumors was 100% at 3 and 6 months. No grade 3 acute
(within 6 months of radiation completion) treatment-related toxicities were identiﬁed.
Conclusions: SMART may allow PTV coverage improvement and/or OAR sparing compared with
nonadaptive SBRT and may widen the therapeutic index of UCT SBRT. In this small prospective
cohort, we found that SMART was clinically deliverable to 100% of patients, although treatment
delivery times surpassed our predeﬁned, timing-based feasibility endpoint. This technique is well
tolerated, offering excellent local control with no identiﬁed acute grade 3 toxicity.
 2018 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Stereotactic body radiation therapy (SBRT) is an
established treatment modality for unresectable primary
or metastatic thoracic malignancies. Increased radiation
dose correlates with increased tumor control, and delivery
of a biologically effective dose of 100 Gy or more has
been found to improve survival outcomes in SBRT for
early-stage lung cancers.1e3 However, within the central
thorax, dose-escalated therapy has previously resulted in
excess toxicity because of the proximity of critical organs
at risk (OARs).4,5 Inherent uncertainties in targeting pre-
cision and accuracy, attributable to both inter- and intra-
fraction OAR motion as well as setup and gating
inaccuracies, may contribute to this risk.
Toxicity risks of SBRT may be highest in ultracentral
thorax (UCT)malignancies. Here we deﬁneUCT tumors as
those with gross tumor volumes (GTVs) directly abutting
the mainstem bronchi, carina, or contents of the medias-
tinum, although some deﬁnitions also include tumors
whose planning target volumes abut or overlap these
structures.6,7 Hypofractionated stereotactic radiation ther-
apy is one reported approach to central and ultracentral
lesions, predicated on the theory that a more fractionated
course, using 6 to 15 fractions (rather than 5 as with
SBRT), could enhance OAR protection.8,9 However, in a
reported series of hypofractionated stereotactic radiation
therapy for ultracentral tumors, toxicity remained a concern
and the radiobiologic evidence for improved OAR protec-
tion using this method is inconclusive.6
As an alternative method, SBRT approaches using
improved image guidance and adjusting for changes in
tumor and OAR anatomy through online adaptive radi-
ation therapy could also improve OAR protection.
Magnetic resonance (MR) image (MRI) guided radiation
therapy (MR-IGRT) offers superior soft tissue visuali-
zation for sites such as the mediastinum and is increas-
ingly practiced in a variety of disease sites.10e12 A
recently published phase 1 trial of stereotactic MR-
guided online adaptive radiation therapy (SMART)
described application of this technique in the abdomen.13
A simulated study of SMART previously indicated po-
tential dosimetric beneﬁts in the UCT, including
improvement of the therapeutic index through daily
treatment plan reoptimization based on daily volumetric
setup imaging and treatment monitoring with cine MR-
guided gating during treatment delivery.14 Prospective
clinical evaluation of this technique to improve the
therapeutic index of SBRT for UCT disease has not
previously been reported.
To prospectively assess the feasibility and safety of
SMART, we a conducted a phase 1 clinical trial of this
technique for oligometastatic and unresectable primary
malignancies. The primary endpoint was feasibility,
deﬁned by delivery of adaptive treatment in <80 minutes
of on-table time for >75% of cases. Here we report the
results of this study in patients with UCT malignancies.
We hypothesized that SMART would be feasible and
deliver ablative radiation doses with acceptable rates of
acute thoracic toxicity.
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Methods and Materials
Patient eligibility
This protocol was approved by Washington University’s
institutional review board (NCT 02264886). Enrolled
patients were considered clinical and technical SBRT
candidates and had oligometastatic or unresectable primary
UCT malignancies. We deﬁned oligometastatic disease as
3 progressive disease sites. Eligible patients had 1 site
amenable to UCT SBRT, were 18 years old, had a
Karnofsky performance status score of 70, had the
capacity to provide consent, and had disease of solid tumor
(nonhematologic) classiﬁcation, excluding small cell
cancers; characteristics are provided in Table 1. Any
preceding systemic therapy was held 1 week before
planned start of SMART, with no plans to reinitiate
systemic therapy for 1 week after SMART completion.
Exclusion criteria comprised history of radiation within the
projected treatment ﬁeld, ongoing receipt of other
investigational agents, uncontrolled intercurrent illness,
pregnancy and/or breastfeeding, or any contraindication to
MRI.
Simulation and initial plan
The initial treatment planning process and details of
treatment simulation, as well as the MR-IGRT treatment
device, its built-in dedicated treatment planning system,
and imaging characteristics, have been previously
described.13,15e17 Brieﬂy, we used a commercially
available MRIdian (ViewRay, Sunnyvale, CA) MR-IGRT
unit, consisting of a low-ﬁeld split-solenoid 0.35 Tesla
MRI unit straddling a ringed gantry with 3 multileaf
collimatoreequipped 60Co heads spaced 120 apart. All
patients underwent computed tomography (CT) and MRI
simulation with custom immobilization, per standard
clinical protocol. Exhale breath-hold simulation CT scans
served as primary image sets for treatment planning
density information, with registration of simulation MR
image sets to aid physician delineation of target volumes
and OARs.
Prescription dose for all plans was 50 Gy in 5 frac-
tions, with goal 95% planning target volume (PTV)
coverage by 95% of prescription dose (47.5 Gy). Pre-
scription coverage was subject to hard OAR constraints,
as delineated in Tables 2 and 3, using a strict isotoxicity
approach. A 5-mm volumetric expansion on the GTV was
used to generate the PTV. A strict isotoxicity approach
was used such that if goal PTV coverage could not be
achieved without OAR constraint violation, then coverage
of the PTV was sacriﬁced to meet OAR constraints.
Online plan adaptation
The online plan adaptation and plan quality assurance
(QA) processes used in this study were summarized pre-
viously.13,15 In short, patients underwent daily volumetric
MRI for localization and setup. The initial plan,
comprising either the simulation-based plan or the most
recently used adapted plan, was loaded onto the image set
of the day, and the treating physician edited contour
volumes manually, as needed. The pre-existing plan was
then assessed on the anatomy of the day. If OAR violation
or an opportunity for PTV coverage improvement was
identiﬁed, a new adaptive plan was generated while the
patient remained on the table. The daily adaptive plan was
then assessed and compared with the pre-existing,
nonadaptive initial plan on the basis of dose to OARs
and target volumes. The patient was then treated with the
plan preferred by the treating physician. A fraction-by-
fraction, strict isotoxicity approach was used to assess
OAR sparing, without OAR point dose accumulation.
Any delivered adaptive treatment plan became the default,
nonadaptive plan for subsequent treatment days.
Treatment delivery and cine MR gating
Standard clinical practices for use of MR guidance and
cine MR gating as performed in this study have been
previously described.13,18 Real-time MR guidance
including planar sagittal cine MR gating on the GTV
(based on the exhale phase during free breathing) was
employed for all fractions. Targets for cine gating window
construction and gating settings were chosen by the
treating physician at the time of each treatment fraction.




Median age (range), y 64 (45-76)
Median tumor size (range), cm 3.1 (1.1-5.6)
Median prior chemotherapy regimens (range) 1 (0-9)
Median KPS (range) 90 (70-90)
Disease histology
Primary non-small cell lung cancer 1
Papillary thyroid carcinoma metastasis 1
Colorectal cancer metastasis 1
Spindle cell sarcoma metastasis 1
Renal cell carcinoma metastasis 1
Disease subsite
Invading pericardium 2
Invading mainstem bronchus 2
Abutting esophagus 1
Acute (within 6 mo) grade 3þ toxicities 0
Late (>6 mo) treatment-related toxicities 1
Esophageal stricture 15 mo posttreatment 1
Abbreviations: KPS Z Karnofsky Performance Status.
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Treatment time and dosimetry data collection
Feasibility, deﬁned by delivery of adaptive treatment
in <80 minutes of on-table time for >75% of cases, was
the primary study endpoint. Study physicians subjectively
designed this endpoint based on the clinical estimation
that patients would not tolerate treatments lasting longer
than 80 minutes. This inference was based on treating
physician opinion of typical patient tolerance of daily
immobilized treatment positioning within the bore of an
MR-IGRT device; at the time of the study there was a
paucity of preceding prospective radiation therapy data to
better estimate patient timing tolerances for MR-IGRT.
Timing data, including door-to-door patient treatment
time and subcomponents such as imaging, recontouring,
replanning, and plan QA times, were prospectively
recorded by the treating radiation therapists. Dosimetry
metrics, including fraction-by-fraction OAR dose, cumu-
lative GTV/PTV dose, and projected dose that would
have been delivered without plan adaptation, were also
prospectively recorded. Current technology is insufﬁcient
to reproducibly identify point volumes of deformable
OARs for dose accumulation. However, GTV/PTV dose
accumulation was achieved by a previously described
method, using rigid alignment of the daily dose distribu-
tion from each fraction to the ﬁrst fraction, based on the
centroid of the GTV volume, and addition of the dose
from all fractions.13
Patient follow-up, outcomes, and statistical
analysis
Patient demographic characteristics and baseline
Response Evaluation Criteria in Solid Tumors (RECIST)
target tumor measurements of the treated lesion were
collected pretreatment and during scheduled study follow-
up at 6 weeks, 3 months, and 6 months after treatment.
Treatment response by RECIST was prospectively
assessed by study physicians at 3 and 6 months after
treatment. Acute thoracic toxicity, deﬁned as toxicity
within 6 months of radiation therapy completion, was
assessed prospectively at 6 weeks, 3 months, and 6
months. Toxicity was graded according to the Common
Terminology Criteria for Adverse Events Version 4.0
(CTCAE v4). Late toxicities were evaluated by treating
physicians through routine clinical care and detailed
retrospective chart review by study physicians. Disease-
free, progression-free, and overall survival metrics were
prospectively assessed at 3 and 6 months posttreatment.
Longer-term outcomes were subsequently determined by
study physicians through careful chart review and routine
clinical appointments. The Kaplan-Meier method was
Table 3 Target volume coverage








PTV V50, % NA 54.9  50.8 77.6 (0-98.9) 73.1  43.3 98.7 (0-100)
PTV V47.5, % 95% 57.4  52.3 86.7 (0.1-100) 75.6  43.1 99.8 (0.5-100)
GTV V50, % 100% 59.3  54.2 96.7 (0-100) 76.2  43.4 100 (0-100)
GTV V47.5, % 100% 60.0  54.0 98.2 (0.5-100) 78.8  43.6 100 (1.1-100)
GTV V45, % 100% 80.7  29.3 99.0 (33.0-100) 86.3  29.8 100 (33.0-100)
GTV max, Gy NA 58.5  10.5 58.1 (47.8-72.3) 62.5  10.3 64.0 (49.1-76.5)
GTV min, Gy NA 48.5  11.1 43.5 (37.9-61.0) 53.0  12.0 53.8 (40.3-70.1)
Abbreviations: GTV Z gross tumor volume; max Z maximum; min Z minimum; NA Z not applicable; PI Z initial nonadaptive plan; PTV Z
planning target volume; SD Z standard deviation.
Table 2 Organ-at-risk dosimetry
Organ at risk Hard constraint No. of PI constraint
violations
Mean  SD Median Range
Uninvolved lung 1500 cm3 <12.5 Gy NA NA NA NA
(lung GTV) 1000 cm3 <13.5 Gy NA NA NA NA
Trachea max V50 Gy <0.2 cm3 3 11.32  1.83 cm3 10.97 cm3 9.68-13.30 cm3
Bronchial tree max V50 Gy <0.2 cm3 NA NA NA NA
Esophageal max V32 Gy 0.5 cm3 3 3.24  1.27 cm3 3.09 cm3 2.05-4.58 cm3
Heart/pericardium V32 Gy 15 cm3 3 23.38  6.67 cm3 25.66 cm3 15.87-28.62 cm3
Cord V25 Gy <1.0 cm3 3 1.87  0.09 cm3 1.84 cm3 1.72-1.89 cm3
Stomach max V33 0.5 cm3 1 1.19 cm3 1.19 cm3 NA
Abbreviations: GTV Z gross tumor volume; NA Z not applicable; max Z maximum; min Z minimum; PI Z initial nonadaptive plan; SD Z
standard deviation.
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used to estimate local progression-free survival. Statistical
analyses were completed using SAS Version 9.4 (SAS
Institute, Inc, Cary, NC).
Results
Patient and tumor characteristics
Five patients were enrolled and treated per protocol to
UCT sites. Four of the 5 patients received treatment to
oligometastatic lesions, and 1 had an unresectable primary
non-small cell lung cancer. Median follow-up time from
completion of therapy was 14 months (range, 8-31
months). A complete summary of patient demographics
and disease characteristics is available in Table 1.
Treatment planning and delivery
All initial plans met hard OAR constraints (Table 2)
based on CT/MRI simulation anatomy. Adaptive plans met
identical hard constraints based on daily volumetric setup
MRI anatomy. All 5 patients completed planned treatment
using a 5-fraction course of SMART, for a total of 25
delivered fractions. Ten of 25 total treatment fractions were
delivered using online adapted plans based on superior
OAR sparing (7 of 10) or improved PTV coverage (3 of
10) compared with the initial, nonadaptive plan. Four out
of 5 patients required adaptive planning for 1 fraction.
One patient had a tumor invading and attached to the
pericardium without other adjacent OARs; the ﬁxed
tumorepericardium spatial relationship was not found to
change, and adaptation was not deemed advantageous in
that patient. Summarization of disease subsites treated and
the clinical reasons for plan adaptation for each patient are
available in Tables 1 and 4.
The primary feasibility endpoint of delivery of >75%
of treatment fractions in 80 minutes was not met.
Although median on-table treatment time was 69 minutes
(range, 22-117 minutes), only 68% (17 of 25) of treatment
fractions were delivered in 80 minutes. Instead, 76%
(19 of 25) of fractions were delivered in 90 minutes. A
detailed breakdown of treatment time components is
provided in Table 4.
OAR constraints
A total of 70% (7 of 10) of plan adaptations were due
to need to reverse 1 hard OAR constraint violation that
would have otherwise occurred had the initial, nonadap-
tive plan been delivered. An example case of plan adap-
tation to reverse OAR constraint violation that would
have otherwise occurred is illustrated in Figure 1. OARs
that would have received excess dose without adaptive
planning included the esophagus (n Z 3 averted viola-
tions), heart (n Z 3), trachea (n Z 3), stomach (n Z 1),
and spinal cord (n Z 3). The magnitude by which con-
straints would have been exceeded was variable, as were
the volumes of OARs that would have received excess
dose; Figure 2 and Table 2 provide detailed summaries of
OAR violations. With online adaptation, 100% of OAR
violations that would have occurred were prevented.
Target volume coverage
Online plan adaptation had variable effects on target
coverage. Plan adaptation was performed in 3 of 10
adapted fractions for the primary indication of improved
PTV coverage (Fig 1). By contrast, in most (5 of 7)
fractions in which adaptation was indicated to reverse an
OAR constraint violation, GTV and PTV coverage were
reduced to protect OARs. An example of such reduction
in target coverage to reverse multiple OAR constraints is
demonstrated by the dose-volume histogram in Figure 1.
In 2 fractions, OAR violations could be reversed
concomitantly with improvements in PTV coverage. One
patient treated for a spindle cell sarcoma metastasis
invading the pericardium required dose reduction in the
original CT simulation plan to 35 Gy to 95% of the PTV
to meet the hard cardiac constraint. No change in tumor/
OAR geometry was identiﬁed during daily MR-guided
treatments, adaptation was not advantageous at any frac-
tion, and the delivered dose remained 35 Gy to the PTV.
Despite need to protect OARs, however, the mean and
median cumulative GTV and PTV coverage were superior
with SMART compared with the projected coverage that
would have been delivered with nonadaptive SBRT.
Improved cumulative coverage with SMART was found
across all recorded metrics of GTV and PTV coverage
(Table 3). In Figure 3, a dose-volume histogram demon-
strates dose accumulation to the GTV for an example
patient.
Table 4 Treatment delivery parameters
Characteristic Number (%) or
Median (range)
Total delivered fractions 25
Total adapted fractions (% of total) 10 (40)
Adapted for 1 OAR violation, % 7 (28)
Adapted only to increase PTV
coverage, %
3 (12)
Median on-table time (range), min 69 (22-117)
Median imaging (volumetric and
gating acquisitions) time (range), min
2 (1-5)
Median recontour time (range), min 8 (2-13)
Median replan time (range), min 11 (8-20)
Median QA time (range), min 4 (2-6)
Median beam-on time (range), min 27 (13-52)
Abbreviations: OAR Z organ at risk; PTV Z planning target vol-
ume; QA Z quality assurance.
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Toxicity
Acute grade 3 CTCAE v4 treatment-related
toxicity events, deﬁned as occurring within 6 months
of SMART completion, were not identiﬁed. With re-
gard to late toxicity, 1 patient treated for an upper
paratracheal spindle cell sarcoma nodal metastasis
abutting the esophagus developed a CTCAE v4 grade 3
benign esophageal stricture 15 months after completion
of radiation therapy, causing dysphagia and requiring
elective endoscopic dilation. A second patient treated
for a pericardial renal cell carcinoma metastasis
(requiring a reduced dose of 35 Gy as per earlier) had
regional progression 8 months after treatment,
including pericardial studding and a metastasis in the
left ventricular outﬂow tract, and developed a symp-
tomatic pericardial effusion requiring pericardial win-
dow placement with subsequent heart failure. This
grade 4 toxicity 8 months after radiation therapy
completion could not be ruled out as possibly related to
radiation treatment but was deemed likely secondary to
disease progression.
Tumor control and survival
Local control of the treated lesion, deﬁnedas stable disease,
partial response, or complete response by RECIST criteria,
was 100%at 3 and 6months. Local progressionefree survival
was100%at3and6months and80%at12monthsbyKaplan-
Meier estimate.One locoregional failure outside the high-dose
region was identiﬁed at 8-month follow-up. Overall survival
was 100% at 6 months and 60% at 12 months. At last follow-
up, 2 patients had no evidence of disease (19-month and
12-month follow-up), including the patient treated for a
primary non-small cell lung cancer (adenocarcinoma). One
patient had locoregional progression resulting in death from
disease (9-month follow-up), and 2 patients had both regional
and distant metastatic progression resulting in cancer-related
death (14- and 16-month follow-up).
Discussion
In this prospective trial, we evaluated the feasibility of
delivering SMART to UCT tumors. Although our
Figure 1 (A) A magnetic resonance (MR)ebased, adaptive plan for fraction 1 (fx1) met all organ-at-risk (OAR) constraints based on
daily setup anatomy from fx1. (B) Application of the fx1 plan to the fx2 MR image of a patient with an upper paratracheal metastasis
(blue colorwash) abutting the esophagus (pink colorwash) resulted in violation of hard esophageal and trachea (green colorwash)
constraints. (C) Daily adaptive planning for fx2 achieved OAR violation reversal while preserving target volume coverage, as deter-
mined by dose-volume histogram comparison (D). (A color version of this ﬁgure is available at https://dx.doi.org/10.1016/j.adro.2018.1
0.003.)
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subjective, clinician-determined timing endpoint was not
met, we found that SMART was clinically deliverable and
treatment was tolerated by 100% of patients. SMART
offered dosimetric gains, including improved OAR
sparing and greater target coverage. Acute grade 3 or
higher toxicities within 6 months of radiation therapy
were not identiﬁed, and control of the treated lesion was
100% at 3 and 6 months. Our ﬁndings suggest that
SMART may offer a safe and novel approach to deliver
ablative doses of radiation therapy to lesions within the
UCT.
The primary endpoint of this study was feasibility of
SMART. Before study initiation, the criteria for feasibility
were subjectively designed by study physicians based
on the perception that patients would not tolerate
>80-minute treatment sessions. Given that this was the
ﬁrst prospective clinical trial of MR-IGRT and of
SMART, there were no available preceding data
regarding patient tolerance of remaining immobilized
within an MRI bore in the treatment position, and thus
this endpoint was chosen. Our endpoint of delivery
of >75% of fractions in 80 minutes was unmet,
although we did achieve delivery of >75% of fractions in
90 minutes, with a median treatment time of 69 minutes.
Nevertheless, although the subjective feasibility criteria
set for this study were unmet, we still conclude that
SMART is clinically deliverable to the UCT. This is
based on the observation that although treatment required
more time than patients were anticipated to tolerate,
treatment was successfully delivered for all patients, and
all patients tolerated all treatment fractions, despite the
length of time for delivery. We note that ﬁrst imple-
mentations of multiple therapy modalities (that have since
become standard of care in radiation oncology), including
intensity modulated radiation therapy and nonadaptive
robotic SBRT, initially required much longer delivery
times.19,20 Since the time of the present study, multiple
improvements to the online adaptive process have been
implemented at our institution, resulting in reduced
treatment times. These include hiring of advanced radia-
tion therapists to assist with recontouring, a more focused
resegmentation window, improved instructions for
covering physicians, and streamlining of QA proced-
ures.21,22 In addition, we recently installed a commer-
cially available MR-guided linear accelerator, which may
offer reduced beam-on times compared with the tri-cobalt
source used in this study. Although treatment times were
somewhat longer than anticipated in this early application
of SMART, it is reasonable to anticipate that organized
efforts toward process and technology improvements will
improve future time demands of MR-IGRT.23
We also found that SMART offered dosimetric gains,
both for OAR sparing and tumor coverage, compared
with nonadaptive SBRT, with no observed grade 3þ
acute toxicity. Online adaptive planning uncovered mul-
tiple unintended OAR constraint violations that would
have otherwise occurred with nonadaptive SBRT.
Although some constraints were minimally exceeded
(Fig 2) and may not have resulted in toxicity, other vio-
lations were severe and may represent the historic portion
of patients experiencing high-grade acute toxicities in
SBRT to the central thorax.4 SMART reversed 100% of
these constraint violations, including multiple point dose
Figure 2 Maximum scaled point doses projected to be deliv-
ered to constraint volumes of organs at risk (OARs) when initial
nonadaptive plans were applied to daily anatomy. Blue circles
indicate goal OAR constraints over 5 fractions. (A color version
of this ﬁgure is available at https://dx.doi.org/10.1016/j.adro.2
018.10.003.)
Figure 3 Example dose-volume histogram (DVH) demon-
strating the fraction-by-fraction delivered gross tumor volume
(GTV) dose using online adaptation for a typical patient with an
ultracentral right upper lobe lung metastasis. Proximity to the
heart required plan adaptation for multiple fractions, with vari-
able adaptive GTV dose escalation and de-escalation, but cu-
mulative GTV dose remained at goal. Dose from adaptive
fractions (red lines) and the projected dose from the original
simulation plan that would have been delivered by nonadaptive
fractions (blue dashed lines) are shown for comparison, as are
the cumulative adaptive versus nonadaptive dose. The treatment
fraction depicted here exempliﬁes the typical cumulative dose
proﬁle for all patients included in the study. (A color version of
this ﬁgure is available at https://dx.doi.org/10.1016/j.adro.2
018.10.003.)
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violations to the heart and proximal airways. Only 1 pa-
tient did not gain dosimetric advantage for OAR protec-
tion through online adaptive planning; in this patient, the
tumor was ﬁxed to the adjacent critical OAR (the heart).
This particular case may highlight a key concept of online
adaptive planning: Therapeutic gains through adaptation
are likely to be most pronounced in clinical scenarios in
which the spatial relationship between tumors and OARs
is variable, whether by tumor response during therapy or
mobility of the OAR relative to the tumor.
Although the size of our cohort (5 patients) is limited,
zero grade 3þ acute toxicities and only 1 radiation-related
reversible late grade 3 toxicity were identiﬁed, despite the
high-risk disease site treated. Although the cohort in this
pilot study is small, a prior study evaluating similarly
ablative dose schedules with SBRT near the central
bronchi reported acute grade 3 or higher toxicity rates of
33% for central thorax patients.24 Similarly, in the classic
report by Timmerman et al,4 46% of patients experienced
severe toxicity within 2 years of treatment. Although
these experiences of substantial toxicity have discouraged
use of highly ablative regimens in the UCT, it is possible
that use of SMART may mitigate some toxicity risks.
Importantly, improvements in OAR sparing across the
cohort did not compromise cumulative target coverage.
Both cumulative GTV and PTV coverage were improved,
on average, with SMART compared with projected
nonadaptive plans. In several fractions, favorable daily
anatomy was observed such that online adaptive planning
could be performed speciﬁcally to increase target
coverage. Local control of the treated lesion was excellent
and compares favorably with other reports of SBRT to the
central and peripheral thorax, with 100% of patients
having control by RECIST criteria at 3 and 6 months
posttreatment.25 The combined dosimetric and clinical
ﬁndings of treatment safety and tumor control with
improved target coverage suggest that SMART may offer
a widened therapeutic index for ablative radiation therapy
treatment in the UCT.
We acknowledge several limitations to this study.
First, although fraction-by-fraction OAR dose was
reduced using SMART in this small initial cohort, point
dose accumulation to OARs was not performed. Dose
deformation and accumulation of dose to OARs is the
subject of ongoing research at our institution. However,
reproducible methods to identify point volumes of
deformable OARs to cumulatively track dose are not
offered by current technology. Our fraction-by-fraction
isotoxicity approach is therefore conservative, although it
does beneﬁcially ensure that no point volume of OAR can
receive excess dose. Additionally, the on-board imaging
component of the MR-IGRT device used in this study
allowed for cine MR monitoring and gating in a single 2-
dimensional plane, and it is possible that unobserved
tumor/OAR motion in other planes during treatment de-
livery could diminish the therapeutic gains achieved
through daily online adaptive planning. Although 3-
dimensional volumetric real-time MR guidance and
techniques to manage and adjust for intrafraction motion
are of interest and may represent future standards of care,
they are not clinically available at this time.26,27 The
imaging component of the device used in this study is also
not of diagnostic quality, with magnet strength of 0.35 T.
However, this low-ﬁeld MRI component has been found
to be sufﬁcient and effective for clinical use in several
clinics, including for SBRT and online adaptive applica-
tions.12,21,28 Finally, although new prospective evidence
is emerging to support a survival beneﬁt of ablative
treatment for oligometastatic disease (as performed for the
majority of patients in this study), use of oligoablation
remains debatable in many tumor histologic types and is
the subject of ongoing study.29e31 However, this clinical
question is beyond the scope of our study, which pri-
marily sought to determine feasibility of SMART as a
novel radiotherapeutic approach to the UCT.
Conclusions
We found that SMART is a clinically deliverable,
dosimetrically advantageous, and well-tolerated technique
for ablation of UCT malignancies. SMART results in
increased OAR sparing and simultaneous improvements
in target coverage compared with traditional SBRT. Our
future interests include further validation of SMART to
the UCT in an expanded patient cohort as well as process
improvements to streamline the clinical integration of
online adaptive techniques for widespread clinical use.
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